Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CAO Sells $37,209.60 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Theodore Alan Huizenga sold 1,632 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $37,209.60. Following the sale, the chief accounting officer owned 48,670 shares of the company’s stock, valued at approximately $1,109,676. The trade was a 3.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Theodore Alan Huizenga also recently made the following trade(s):

• On Monday, December 29th, Theodore Alan Huizenga sold 85 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $34.38, for a total value of $2,922.30.

Ultragenyx Pharmaceutical Trading Down 1.6%

RARE opened at $21.46 on Friday. The business has a 50 day moving average of $23.30 and a 200-day moving average of $29.14. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -3.67 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.41 and a 1-year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same quarter in the previous year, the company earned ($1.39) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 25.5% compared to the same quarter last year. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analyst Upgrades and Downgrades

RARE has been the topic of several research reports. Wedbush restated a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Jefferies Financial Group lowered their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating on the stock in a research report on Tuesday, December 30th. Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Leerink Partners decreased their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 30th. Finally, Barclays lowered their price target on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, November 24th. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $68.29.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RARE. Jacobs Levy Equity Management Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 614.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock valued at $65,205,000 after purchasing an additional 1,864,164 shares in the last quarter. Norges Bank bought a new position in Ultragenyx Pharmaceutical during the 4th quarter valued at about $29,004,000. Millennium Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 787.6% during the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock valued at $20,255,000 after purchasing an additional 781,431 shares during the last quarter. Vestal Point Capital LP acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $22,560,000. Finally, Russell Investments Group Ltd. grew its stake in Ultragenyx Pharmaceutical by 599.2% during the third quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock worth $25,281,000 after buying an additional 720,256 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.